High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML

(2010) J. A. Pollard et al.   BLOOD

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group

(2009) P. A. Ho et al.   BLOOD

CEBPA resembles Roman god Janus

(2009) I. H. I. M. Hollink et al.   BLOOD

Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia

(2009) I. H. I. M. Hollink et al.   BLOOD

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

(2009) B. J. Wouters et al.   BLOOD

Cytogenetics of pediatric acute myeloid leukemia

(2009) Kalliopi N. Manola   EUROPEAN JOURNAL OF HAEMATOLOGY

Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study

(2009) A M Willasch et al.   LEUKEMIA

Targeted Therapies: The Rare Cancer Paradigm

(2009) Marco A. Pierotti et al.   Molecular Oncology

Monitoring minimal residual disease in acute myeloid leukaemia withNPM1mutations by quantitative PCR: clonal evolution is a limiting factor

(2008) Christina Papadaki et al.   BRITISH JOURNAL OF HAEMATOLOGY

Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): Comparison with WT1 gene expression

(2008) Eva Barragan et al.   CLINICA CHIMICA ACTA

Outcome for children with relapsed acute myeloid leukemia in the Netherlands following initial treatment between 1980 and 1998: survival after chemotherapy only?

(2008) B. F. Goemans et al.   HAEMATOLOGICA

Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML

(2008) I H I M Hollink et al.   LEUKEMIA

Targeting the leukemic stem cell: the Holy Grail of leukemia therapy

(2008) N Misaghian et al.   LEUKEMIA

Significance of age in acute myeloid leukemia patients younger than 30 years

(2007) Ursula Creutzig et al.   CANCER